A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 305
- Registration Number
- NCT05365581
- Locations
- 🇰🇷
Site KR82003, Seocho-gu, Seoul, Korea, Republic of
🇰🇷Site KR82005, Seodaemun-gu, Seoul, Korea, Republic of
🇰🇷Site KR82001, Guro-gu, Seoul, Korea, Republic of
A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05217901
- Locations
- 🇺🇸
Labcorp CRU, Madison, Wisconsin, United States
A Study to Find a Suitable Dose of ASP8731 and Check for Medical Problems at Each Dose in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05167526
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT05117294
- Locations
- 🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸Pinnacle Research Group, Anniston, Alabama, United States
A Study of ASP1570 Taken by Itself or With Pembrolizumab in Adults With Solid Tumors
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT05083481
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸California Research Institute, Los Angeles, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT05062577
A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 453
- Registration Number
- NCT05033886
- Locations
- 🇫🇮
Site FI35803, Oulu, Finland
🇵🇱Site PL48013, Bydgoszcz, Poland
🇳🇴Site NO47001, Hamar, Norway
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
- Conditions
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT05014139
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸UCLA Department of Medicine - Hematology & Oncology, Los Angeles, California, United States
🇺🇸James Cancer Hospital / Ohio State University, Columbus, Ohio, United States
A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04942964
- Locations
- 🇺🇸
Orlando Clinical Research Center, Inc, Orlando, Florida, United States
🇺🇸Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04939701
- Locations
- 🇺🇸
NYU Perlmutter Cancer Center, New York, New York, United States
🇺🇸Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸The University of Chicago Medicine, Chicago, Illinois, United States